Swiss group ACTELION has acquired another Swiss company, AXOVAN, for the sum of CHF 60 million. This amount could be increased to CHF 252 million according to sales prospects. The move will consolidate ACTELION's position on the market for treatment based on controlling patients' blood pressure.